Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Multiple Myeloma 14Lymphoma, Non-Hodgkin 10Breast Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell 5Lymphoma 5Solid Tumors 4Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 4Melanoma 4Leukemia, Myeloid, Acute 4Leukemia, Lymphocytic, Chronic, B-Cell 4Arthritis, Rheumatoid 4Ovarian Neoplasms 3Lymphoma, Follicular 3Leukemia 3Hematologic Neoplasms 3Cytokine Release Syndrome 3Colorectal Neoplasms 3Burkitt Lymphoma 3Urinary Bladder Neoplasms 2Respiratory Distress Syndrome 2Pancreatic Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, Mantle-Cell 2Fallopian Tube Neoplasms 2Craniopharyngioma 2Carcinoma, Hepatocellular 2

Interventions

tocilizumab 1temsirolimus 1siltuximab 1Zidovudine 1Valproic Acid 1Valganciclovir 1Sirolimus 1Rituximab 1Nelfinavir 1Immunoglobulin G 1Genetic Testing 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Castleman Disease × tocilizumab × Clear all
NCT01441063 2020-10-27

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
8 enrolled 18 charts
LymphoidSarcoma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Castleman Disease, Sarcoma, Kaposi

Data powered by HemOnc (CC BY 4.0) Colophon âš¡